## Stage IA Endometrial Cancer — Adjuvant Management **Key Point:** Stage IA endometrial cancer (grade 1–2, no myometrial invasion, no LVSI, negative nodes) has excellent prognosis with surgery alone and does NOT require adjuvant chemotherapy. ### Risk Stratification in Early-Stage Endometrial Cancer | Risk Category | Myometrial Invasion | Grade | LVSI | Adjuvant Therapy | |---|---|---|---|---| | **Low risk** | Absent or superficial | 1–2 | No | Observation | | **Intermediate risk** | Superficial | 3 OR any grade with LVSI | Yes/No | Vaginal brachytherapy (consider) | | **High-intermediate risk** | Deep or absent | 1–2 with risk factors | Variable | Vaginal brachytherapy ± external RT | | **High risk** | Any | 3 | Any | Chemotherapy ± RT | **High-Yield:** This patient has **all favorable features** — grade 1, no myometrial invasion, no LVSI, negative nodes. The 5-year recurrence-free survival exceeds 95% with surgery alone. ### Why Chemotherapy Is Not Indicated Here 1. **No myometrial invasion** — the strongest predictor of lymph node metastases and distant recurrence 2. **No LVSI** — absence of lymphovascular space invasion significantly reduces metastatic risk 3. **Negative pelvic nodes** — confirmed by surgical staging 4. **Grade 1** — low nuclear grade associated with excellent prognosis **Clinical Pearl:** Adjuvant chemotherapy (carboplatin–paclitaxel) is reserved for stage III–IV disease, grade 3 tumors with myometrial invasion, or high-risk histologies (serous, clear cell). It is NOT used in low-risk stage IA disease. **Tip:** In NEET PG exams, recognize that **observation alone** is the correct answer for early-stage, low-risk endometrial cancer. Overtreatment is a common distractor.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.